AGL — Agilon Health, Inc.

AGL Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Membership: Ended Q4 2025 with 511,000 Medicare Advantage members and 114,000 ACO REACH members. Expected to reduce membership to approximately 430,000 in 2026 due to market exits and a disciplined contracting approach.
• Revenue: Q4 revenue was $1.57 billion, totaling $5.93 billion for the full year. Revenue impacted by lower-than-expected risk adjustment revenue and market exits.
• Medical Margin: Q4 medical margin was negative $74 million, with a full-year margin of negative $57 million, reflecting elevated cost trends and market exits.
• Adjusted EBITDA: Q4 adjusted EBITDA was negative $142 million, with a full-year total of negative $296 million. ACO REACH contributed positively with an adjusted EBITDA of $41 million for the year.
• Cost Trends: Full-year medical cost trend was approximately 6.5%, with Q4 trends at 7.4%, influenced by increased inpatient stays.

2. Strategic Updates and Business Highlights

• Focused on operational discipline and transformation to improve long-term profitability.
• Advanced clinical pathways and quality programs aimed at enhancing care management for chronic conditions, with significant adoption in heart failure programs.
• Implemented cost reduction initiatives totaling $35 million, exceeding prior expectations.
• Strengthened data analytics capabilities to improve risk assessment and intervention strategies.
• Continued emphasis on quality performance, achieving an average of 4.2 stars across the network.

3. Forward Guidance and Outlook

• 2026 Expectations: Projected revenue between $5.41 billion and $5.58 billion, with medical margin anticipated between $300 million and $350 million. Adjusted EBITDA expected to be breakeven at the midpoint.
• Anticipated membership growth to 525,000 to 540,000 members, with a focus on profitability over growth.
• Cost trend for 2026 expected at 7.5%, with a net trend of 7% after considering payer bids.
• Continued investment in quality performance and clinical pathways to drive improved patient outcomes and cost management.

4. Bad News, Challenges, or Points of Concern

• Disappointment with CMS's advanced rate notice, which does not adequately address rising costs and utilization trends.
• Elevated medical cost trends, particularly in Q3, raised concerns about future profitability and cost management.
• Membership reduction due to exiting unprofitable payer contracts, impacting revenue and growth potential.
• Limited claims visibility at year-end created uncertainty in forecasting and financial planning.

5. Notable Q&A Insights

• Management acknowledged the challenges in navigating elevated inpatient costs and expressed caution in estimating future trends.
• Discussions highlighted the need for continued focus on disciplined contracting and risk management to improve margins.
• The potential for further cost reductions was acknowledged, with emphasis on automation and technology.
• Management reiterated confidence in their clinical pathways and quality initiatives as key drivers for future performance, despite the challenging macro environment.

Overall, while AGL made progress in its transformation efforts and operational discipline, it faces significant challenges related to cost trends, membership stability, and external regulatory pressures. The outlook for 2026 is cautiously optimistic, with a focus on profitability and quality improvements.